Drug or treatment

Durvalumab clinical trials

• 104Clinical trials
• 3New in 30 days
• 48Countries

Newest trials

All recruiting trials (104)

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Durvalumab with FLOT before and after surgery for resectable gastric/GEJ cancer in Chinese patients

  This trial tests whether adding durvalumab to FLOT chemotherapy before and after surgery helps Chinese patients with resectable gastric or gastroesophageal junction cancer.

  Recruiting at 11 sites Phase 3 AstraZeneca · Beijing and 40 other locations · NCT07877818

• Zolbetuximab added to FLOT and durvalumab before surgery for CLDN18.2-positive gastric/GEJ cancer

  This study tests whether adding zolbetuximab to FLOT chemotherapy plus durvalumab can improve tumor response before surgery in adults with CLDN18.2-positive gastric or GEJ cancer.

  Recruiting Phase 2 National Cancer Center, Japan · Saitama and 3 other locations · NCT07872722

• Alternating chemo-immunotherapy and FGFR inhibitor for FGFR-positive biliary tract cancer

  This phase 2 trial tests whether alternating gemcitabine/cisplatin with durvalumab and the FGFR2 inhibitor pemigatinib can help people with unresectable or metastatic biliary tract cancers that have FGFR alterations.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07780838

• Durvalumab plus histotripsy for intrahepatic cholangiocarcinoma

  This study tests whether adding histotripsy to ongoing durvalumab helps people with advanced intrahepatic cholangiocarcinoma by boosting the immune response and checking safety.

  Recruiting Phase 2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07766187

• Futibatinib and immunotherapy with chemo as first-line treatment for advanced biliary tract cancer

  A first-line treatment test combines Futibatinib with Zimberelimab and Gemcitabine/Cisplatin to see if it improves survival in people with unresectable or advanced biliary tract cancer.

  Recruiting at 4 sites Phase 3 Taiho Pharmaceutical Co., Ltd. · Brisbane and 20 other locations · NCT07710885

• Adjuvant durvalumab with GEMOX/GC chemotherapy followed by lenvatinib vs capecitabine in biliary tract cancer after surgery

  This trial tests whether adding durvalumab with GEMOX/GC chemotherapy followed by lenvatinib after surgery helps biliary tract cancer patients stay cancer-free longer than capecitabine alone.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07679399

• Can an imaging tracer help predict if cholangiocarcinoma patients will respond to standard therapy

  This study tests whether an imaging tracer called [18F]FTT used with PET/CT can predict how newly diagnosed cholangiocarcinoma patients will respond to the standard treatment of gemcitabine, cisplatin, and durvalumab.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07673341

• STRIDE combination in advanced liver cancer: a first-line look at tremelimumab plus durvalumab

  This study tests tremelimumab plus durvalumab as a first-line treatment in adults with advanced or unresectable hepatocellular carcinoma to see how it affects liver health, quality of life, effectiveness, and safety.

  Recruiting at 17 sites AstraZeneca · Ancona and 23 other locations · NCT07607769

• Calderasib plus durvalumab in KRAS G12C NSCLC after chemo-radiation

  This trial tests whether calderasib plus durvalumab can help people with locally advanced KRAS G12C NSCLC who have completed chemotherapy and radiation, compared with placebo plus durvalumab.

  Recruiting at 115 sites Phase 3 Merck Sharp & Dohme LLC · Savannah, Georgia and 114 other locations · NCT07554339

• Lurbinectedin plus durvalumab for extensive-stage small-cell lung cancer after initial treatment

  This study tests whether adding durvalumab to lurbinectedin as maintenance after initial therapy helps people whose ES-SCLC has not progressed.

  Recruiting at 6 sites Phase 2 Jazz Pharmaceuticals · Los Angeles, California and 5 other locations · NCT07459634

• Subcutaneous durvalumab plus hyaluronidase dose-finding and safety for solid tumors

  This study will test whether a subcutaneous (under-the-skin) injection of durvalumab with hyaluronidase gives similar blood levels and is safe for people with certain advanced solid tumors, including unresectable liver cancer and specific forms of lung cancer.

  Recruiting at 14 sites Phase 1 AstraZeneca · Fitzroy and 18 other locations · NCT07391670

• Pumitamig versus durvalumab after chemoradiation for unresectable stage III NSCLC

  This trial tests whether Pumitamig or durvalumab works better to keep unresectable stage III non-small cell lung cancer from coming back after concurrent chemoradiation.

  Recruiting at 201 sites Phase 3 Bristol-Myers Squibb · Daphne, Alabama and 258 other locations · NCT07361497

• Sacituzumab govitecan with atezolizumab or durvalumab as maintenance for extensive-stage small cell lung cancer

  This study tests whether adding sacituzumab govitecan to ongoing atezolizumab or durvalumab can better control tumors in adults with extensive-stage small cell lung cancer after initial platinum-based chemotherapy.

  Recruiting Phase 2 Henry Ford Health System · Detroit, Michigan · NCT07339059

• Repeated endobiliary radiofrequency ablation with durvalumab, gemcitabine, and cisplatin for unresectable extrahepatic bile duct cancer

  This trial tests whether adding repeated endobiliary radiofrequency ablation to standard durvalumab plus gemcitabine and cisplatin helps people with unresectable extrahepatic bile duct cancer live longer.

  Recruiting at 8 sites Aichi Medical University · Aichi and 7 other locations · NCT07235007

• Rilvegostomig or durvalumab with gemcitabine–cisplatin for first-line biliary tract cancer

  This compares rilvegostomig plus gemcitabine–cisplatin to durvalumab plus gemcitabine–cisplatin as first treatment for people with advanced biliary tract cancer.

  Recruiting at 153 sites Phase 3 AstraZeneca · Birmingham, Alabama and 182 other locations · NCT07221253

• RBS2418 with tremelimumab and durvalumab for advanced unresectable liver cancer

  This trial will test whether adding RBS2418 to tremelimumab plus durvalumab helps adults with advanced, unresectable hepatocellular carcinoma.

  Recruiting at 4 sites Phase 2 Riboscience, LLC. · Baltimore, Maryland and 3 other locations · NCT07175441

• Celecoxib with durvalumab and tremelimumab for advanced liver cancer

  This phase II trial tests whether adding the oral drug celecoxib to the immunotherapy drugs durvalumab and tremelimumab helps people with advanced or metastatic liver cancer.

  Recruiting at 3 sites Phase 2 Emory University · Atlanta, Georgia and 3 other locations · NCT07174570

• Durvalumab consolidation after chemoradiation for limited-stage small-cell lung cancer in China

  This project will test durvalumab given after chemoradiation in people with limited‑stage small‑cell lung cancer who have not progressed, to see how well it works and how safe it is in routine care.

  Recruiting at 20 sites AstraZeneca · Beijing and 20 other locations · NCT07161388

• Y-90 internal liver radiation followed by tremelimumab and durvalumab for liver cancer with portal vein thrombosis

  This will test whether Y-90 selective internal radiation (SIRT) followed by tremelimumab and durvalumab helps people with non-resectable hepatocellular carcinoma that involves the portal vein.

  Recruiting Phase 2 Center Eugene Marquis · Grenoble and 5 other locations · NCT07122089

• Emavusertib with cisplatin, gemcitabine, and durvalumab for untreated advanced biliary tract cancer

  This trial tests whether adding emavusertib to standard cisplatin, gemcitabine, and durvalumab helps adults with untreated advanced or metastatic biliary tract cancer.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07107750

• Durvalumab consolidation after chemoradiotherapy for limited-stage small cell lung cancer

  This trial tests whether giving durvalumab alongside and after standard chemoradiotherapy helps people with limited-stage small cell lung cancer have better tumor control and longer survival.

  Recruiting at 2 sites Phase 2 Tongji Hospital · Zhengzhou, Henan and 1 other locations · NCT07055581

• Radiation therapy followed by immune therapy and surgery for hepatocellular carcinoma

  This trial tests whether adding durvalumab and tremelimumab to radiation therapy before surgery helps people with resectable liver cancer.

  Recruiting Phase 3 Hamilton Health Sciences Corporation · Hamilton, Ontario and 1 other locations · NCT07027436

• FOLFOX with durvalumab, bevacizumab, and targeted radiation to try to make advanced liver cancer operable

  This will try combining liver-directed FOLFOX chemotherapy, durvalumab, bevacizumab, and focused radiation to see if intermediate or advanced liver cancer can be shrunk enough for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07012798

• Photon radiotherapy plus tremelimumab and durvalumab for intermediate or advanced hepatocellular carcinoma

  This trial tests whether adding targeted photon radiotherapy to tremelimumab plus durvalumab helps people with unresectable intermediate or advanced (BCLC B or C) hepatocellular carcinoma respond better to treatment.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06999707

• Proton radiation with tremelimumab and durvalumab for BCLC stage B/C hepatocellular carcinoma

  This will test whether adding precise proton radiation to tremelimumab plus durvalumab helps people with unresectable BCLC stage B or C hepatocellular carcinoma.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06999694

• Durvalumab with or without Olaparib for people with endometrial cancer in Korea

  This study will see if Durvalumab, with or without Olaparib, is safe and works for people in Korea who are prescribed these drugs for endometrial cancer as part of routine care.

  Recruiting AstraZeneca · Seoul · NCT06995833

• Using durvalumab with chemotherapy for muscle-invasive bladder cancer

  This study is testing if adding a new immune therapy called durvalumab to standard chemotherapy can help people with muscle-invasive bladder cancer before they have surgery.

  Recruiting at 48 sites Phase 2 AstraZeneca · Chermside and 58 other locations · NCT06960577

• Datopotamab deruxtecan with or without durvalumab for PD-L1–negative metastatic triple-negative breast cancer

  This will see if adding durvalumab to datopotamab deruxtecan helps people with PD-L1–negative advanced or metastatic triple-negative breast cancer live longer without their disease getting worse.

  Recruiting Phase 2 Queen Mary University of London · London and 1 other locations · NCT06954480

• Evaluating a combination treatment for advanced liver cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it helps patients live longer and feel better.

  Recruiting Phase 1/2 Seoul National University Hospital · Seoul · NCT06911255

• Chemoradiotherapy followed by durvalumab for stage III lung cancer

  This study is testing if giving a combination of chemotherapy, radiation, and the immunotherapy durvalumab can help people with stage III lung cancer who couldn't initially have surgery, to see if it improves their chances of survival.

  Recruiting Phase 4 Amsterdam UMC, location VUmc · Amsterdam · NCT06908070

• Durvalumab plus tremelimumab with or without liver-directed GEMOX chemotherapy for hepatocellular carcinoma

  This trial tests whether adding hepatic arterial infusion chemotherapy (GEMOX) to the immunotherapy combination durvalumab plus tremelimumab helps people with hepatocellular carcinoma who have a high tumor burden in the liver.

  Recruiting at 5 sites Phase 2/3 Unicancer · Bordeaux and 10 other locations · NCT06904170

• Examining the effectiveness and safety of Durvalumab and Olaparib in endometrial cancer patients

  This study is testing how well and safely a combination of Durvalumab and Olaparib works for women with advanced or recurrent endometrial cancer who are receiving specific first-line treatments.

  Recruiting at 49 sites AstraZeneca · Amberg and 48 other locations · NCT06890273

• Durvalumab + Tremelimumab with or without Lenvatinib for unresectable liver cancer

  This trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) helps people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

  Recruiting at 13 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 12 other locations · NCT06880523

• Combining HAIC with Durvalumab and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma

  This study is testing a new treatment combining chemotherapy with two other drugs to see if it can help people with advanced bile duct cancer feel better and live longer.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT06859684

• Combination of immunotherapy and surgery for advanced lung cancer

  This study is testing if a new combination of immunotherapy and surgery can help people with advanced lung cancer live longer and healthier compared to current treatments.

  Recruiting at 4 sites Phase 2 University Hospital, Bonn · Freiburg im Breisgau, Baden-Wurttemberg and 4 other locations · NCT06810609

• Biomarkers to predict outcomes in liver cancer treated with tremelimumab plus durvalumab

  This study will test whether blood biomarkers can predict how adults with unresectable or metastatic hepatocellular carcinoma respond to tremelimumab plus durvalumab (STRIDE regimen).

  Recruiting at 10 sites Centre Hospitalier Universitaire de Besancon · Besançon and 9 other locations · NCT06796114

• Biomarker-guided personalized maintenance treatments for extensive-stage small cell lung cancer

  This phase II trial tests whether biomarker tests on a patient's tumor can guide personalized maintenance drug combinations for people with extensive-stage small cell lung cancer.

  Recruiting at 146 sites Phase 2 SWOG Cancer Research Network · Loma Linda, California and 147 other locations · NCT06769126

• Pemigatinib plus durvalumab for previously treated advanced intrahepatic cholangiocarcinoma with FGFR2 fusion

  This will test whether combining the FGFR inhibitor pemigatinib with the immunotherapy durvalumab helps adults with advanced intrahepatic cholangiocarcinoma that has an FGFR2 fusion and who have already received prior treatment.

  Recruiting at 3 sites Phase 2 Hoosier Cancer Research Network · Birmingham, Alabama and 2 other locations · NCT06728410

• Combining Surufatinib with Gemcitabine, Cisplatin, and Durvalumab/Pembrolizumab for Advanced Biliary Tract Cancer

  This study is testing if adding a new drug called surufatinib to the standard treatment for advanced biliary tract cancer can help patients live longer and feel better.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT06708858

• Combining Zanzalintinib with Immunotherapy for Liver Cancer

  This study is testing a new combination of a cancer drug and immunotherapy to see if it can help people with advanced liver cancer feel better and fight their disease.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania and 2 other locations · NCT06698250

• Evaluating immunotherapy for colorectal and endometrial cancer

  This study is testing a new immunotherapy treatment for people with colorectal or endometrial cancer to see if a combination of two drugs can help them better than just one.

  Recruiting Phase 2 Vall d'Hebron Institute of Oncology · Barcelona · NCT06680739

• Repeat chest radiation followed by durvalumab plus ceralasertib for recurring Stage III NSCLC after PACIFIC

  This trial will test whether giving repeat chest radiotherapy followed two weeks later by the immunotherapy durvalumab together with the drug ceralasertib helps people with Stage III non-small cell lung cancer who have a thoracic relapse after the PACIFIC treatment.

  Recruiting at 4 sites Phase 2 Mario Negri Institute for Pharmacological Research · Brescia and 8 other locations · NCT06680050

• Combining JNJ-90301900 with chemotherapy and radiation for advanced lung cancer

  This study is testing if adding a new drug called JNJ-90301900 to standard chemotherapy and radiation can help people with advanced lung cancer respond better to treatment.

  Recruiting at 44 sites Phase 2 Johnson & Johnson Enterprise Innovation Inc. · La Jolla, California and 44 other locations · NCT06667908

• Combining Tumor-Treating Fields with Durvalumab and Gemcitabine/Cisplatin for Biliary Tract Cancers

  This study is testing a new treatment that combines Tumor-Treating Fields with standard chemotherapy to see if it helps people with advanced biliary tract cancers who haven't had treatment before.

  Recruiting Jiangsu Healthy Life Innovation Medical Technology Co., Ltd · Hefei · NCT06611345

• Durvalumab with gemcitabine, cisplatin, and nab‑paclitaxel for advanced or metastatic gallbladder cancer

  This trial will test whether adding the immune drug durvalumab to chemotherapy (gemcitabine, cisplatin, and nab‑paclitaxel) helps adults with unresectable locally advanced or metastatic gallbladder cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06591650

• Targeting driver oncogenes in biliary tract cancer with a personalized peptide vaccine plus durvalumab and tremelimumab

  This trial will test whether a personalized mutant peptide vaccine given with durvalumab and tremelimumab is safe and stimulates an immune response in people with advanced biliary tract cancer after first-line chemotherapy and anti–PD-(L)1 therapy.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06564623

• Combining CTX-009 with standard chemotherapy for advanced biliary tract cancer

  This study is testing if adding a new drug called CTX-009 to standard chemotherapy can help people with advanced biliary tract cancer live longer and feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06548412

• Treatment for advanced liver cancer with specific cirrhosis

  This study is testing a new combination treatment for advanced liver cancer in patients with specific cirrhosis to see if it can help them better than current options, especially focusing on those from underserved communities.

  Recruiting Phase 2 The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT06526104

• Combining Durvalumab and Monalizumab for Bladder Cancer Treatment

  This study is testing a combination of two drugs, durvalumab and monalizumab, to see if they can help people with certain types of bladder cancer that haven't responded to standard treatment.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · San Francisco, California and 4 other locations · NCT06503614

• Examining the effectiveness of a treatment combination in patients with advanced lung cancer

  This study is testing a new treatment combination for patients with advanced lung cancer to see how well it works based on their specific genetic markers.

  Recruiting at 27 sites AstraZeneca · Bad Homburg and 29 other locations · NCT06494540

• Comparing T-DXd with Rilvegostomig to Standard Treatment for Advanced HER2-expressing Biliary Tract Cancer

  This study is testing if a new combination treatment for advanced biliary tract cancer can work better than the usual options for adults with this condition.

  Recruiting at 232 sites Phase 3 AstraZeneca · Scottsdale, Arizona and 271 other locations · NCT06467357

• Treatment for extensive stage extrapulmonary small cell carcinoma using durvalumab with chemotherapy

  This study is testing if a new combination of durvalumab with chemotherapy can help people with advanced extrapulmonary small cell carcinoma feel better and live longer.

  Recruiting Phase 2 Gruppo Oncologico Italiano di Ricerca Clinica · Reggio Emilia · NCT06464068

• Combining Durvalumab and Olaparib for Advanced Cholangiocarcinoma Treatment

  This study is testing if combining two drugs, durvalumab and olaparib, can help people with advanced cholangiocarcinoma feel better and live longer after their initial chemotherapy.

  Recruiting at 7 sites Phase 2 Australasian Gastro-Intestinal Trials Group · Camperdown, New South Wales and 7 other locations · NCT06441747

• Combining Durvalumab with Radiofrequency Ablation for Treating Extrahepatic Cholangiocarcinoma

  This study is testing if combining a new immunotherapy with radiofrequency ablation and chemotherapy can help people with a type of bile duct cancer that can't be surgically removed.

  Recruiting at 12 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Aachen and 11 other locations · NCT06440993

• Combination of durvalumab with chemotherapy for lung cancer

  This study is testing if a new combination of chemotherapy and a drug called durvalumab can help people with advanced lung cancer feel better and improve their treatment outcomes.

  Recruiting at 3 sites Phase 2 Gruppo Oncologico Italiano di Ricerca Clinica · Bologna, BO and 14 other locations · NCT06418087

• Combining Durvalumab with Etoposide and Platinum for Lung Cancer Treatment

  This study is testing if combining a new immune therapy with chemotherapy can help people with advanced lung cancer feel better and live longer.

  Recruiting at 2 sites Phase 2 Centre Leon Berard · Aix-en-Provence and 30 other locations · NCT06393816

• Combining radioembolization and biological therapy for advanced bile duct cancer

  This study is testing a new treatment for advanced bile duct cancer that combines a special type of radiation therapy with immune and chemotherapy drugs to see if it can work better for patients whose tumors can't be removed.

  Recruiting at 4 sites Phase 2 IRCCS San Raffaele · Bergamo and 3 other locations · NCT06375915

• Combining Durvalumab with Chemoradiotherapy for Limited Stage Small Cell Lung Cancer

  This study is testing if adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with limited stage small cell lung cancer live longer and feel better.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT06371482

• Neoadjuvant chemotherapy and immunotherapy for advanced cholangiocarcinoma

  This study is testing a combination of chemotherapy and immunotherapy before surgery to see if it can help people with advanced cholangiocarcinoma have fewer cancer recurrences within a year after their operation.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples, Italia and 5 other locations · NCT06341764

• Combining iadademstat with immunotherapy for advanced small cell lung cancer

  This study is testing whether adding a new drug called iadademstat to standard immunotherapy can help people with advanced small cell lung cancer live longer without their disease getting worse.

  Recruiting at 33 sites Phase 1/2 National Cancer Institute (NCI) · Duarte, California and 42 other locations · NCT06287775

• Evaluating Durvalumab After Chemotherapy and Surgery for Early-stage Lung Cancer

  This study is testing if adding an immunotherapy drug called durvalumab after chemotherapy and surgery can help people with early-stage lung cancer live longer without the disease coming back.

  Recruiting at 29 sites Phase 3 ETOP IBCSG Partners Foundation · Camperdown, New South Wales and 43 other locations · NCT06284317

• Combining futibatinib and durvalumab before bladder cancer surgery for patients who can't use cisplatin

  This study is testing if combining two drugs, futibatinib and durvalumab, before bladder cancer surgery can help patients who can't take cisplatin feel better and improve their chances of recovery.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Ann Arbor, Michigan and 2 other locations · NCT06263153

• Observational study on durvalumab treatment for liver cancers

  This study is trying to see how well a treatment called durvalumab works for people with advanced liver cancers that can’t be surgically removed.

  Recruiting at 160 sites AstraZeneca · Birmingham, Alabama and 160 other locations · NCT06252753

• Combining durvalumab with radiochemotherapy and stereotactic radiotherapy for extensive-stage small-cell lung cancer

  This study is testing if adding the immunotherapy drug durvalumab to radiochemotherapy and targeted radiation can help people with extensive-stage small-cell lung cancer feel better and manage their disease.

  Recruiting at 5 sites Phase 2 Universität des Saarlandes · Augsburg, Bavaria and 4 other locations · NCT06223711

• Comparing Dato-DXd with or without Durvalumab to standard chemotherapy for advanced triple-negative breast cancer

  This study is testing if a new treatment called Dato-DXd, with or without another drug called durvalumab, can help people with advanced triple-negative breast cancer live longer without their cancer getting worse compared to standard chemotherapy.

  Recruiting at 242 sites Phase 3 AstraZeneca · Daphne, Alabama and 317 other locations · NCT06103864

• Combining Durvalumab with XELOX chemotherapy for advanced gastrointestinal neuroendocrine carcinoma

  This study is testing a new treatment that combines durvalumab with XELOX chemotherapy to see if it helps people with advanced gastrointestinal neuroendocrine carcinoma.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06070740

• Using durvalumab and oleclumab before surgery for pancreatic cancer

  This study is testing if giving two immune-boosting treatments before surgery can help people with pancreatic cancer have better outcomes.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT06060405

• Combining radioembolization with immunotherapy for advanced bile duct cancer

  This study is testing a new treatment that combines a special type of radiation therapy with immunotherapy drugs to see if it can help patients with advanced bile duct cancer who can't have surgery.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT06058663

• Combining an immunotherapy drug with standard chemotherapy for advanced breast cancer

  This study is testing if adding an immunotherapy drug called durvalumab to standard chemotherapy can help people with advanced hormone receptor-positive, HER2-negative breast cancer live longer and feel better.

  Recruiting at 552 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 564 other locations · NCT06058377

• Combination of immunotherapy and chemotherapy for mesothelioma treatment

  This study is testing whether combining two immunotherapy drugs with chemotherapy can help people with a type of lung cancer called mesothelioma live longer without their cancer coming back.

  Recruiting Phase 1/2 Baylor College of Medicine · Durham, North Carolina and 1 other locations · NCT05932199

• Combination treatment for extensive stage small cell lung cancer

  This study is testing a new combination treatment for people with extensive stage small cell lung cancer to see if it helps them live longer and feel better.

  Recruiting at 4 sites Phase 2 Hoosier Cancer Research Network · Indianapolis, Indiana and 3 other locations · NCT05903092

• Triple treatment for advanced liver cancer patients

  This study is testing two different ways to treat advanced liver cancer to see which one works better for patients who can't have surgery.

  Recruiting at 3 sites Phase 2 Ludwig-Maximilians - University of Munich · Munich and 2 other locations · NCT05844046

• Testing a new drug combination for HER2-positive inflammatory breast cancer

  This study is testing a new combination of two drugs to see if they can safely and effectively treat people with stage III HER2-positive inflammatory breast cancer who haven't had treatment before.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT05795101

• Combination treatment for early-stage non-small cell lung cancer

  This study is testing a new combination treatment with IPH5201, durvalumab, and standard chemotherapy for people with early-stage non-small cell lung cancer to see if it helps them do better after surgery.

  Recruiting at 10 sites Phase 2 Innate Pharma · St. Petersburg, Florida and 29 other locations · NCT05742607

• Combination therapy for premenopausal women with advanced ER positive breast cancer

  This study is testing different combinations of medications to see if they can help premenopausal women with advanced breast cancer that hasn't improved with previous treatments.

  Recruiting Phase 2 National Taiwan University Hospital · Taipei · NCT05720260

• Quick start of Durvalumab after chemotherapy and radiation for advanced lung cancer

  This study is testing if starting Durvalumab treatment right after chemotherapy and radiation can help people with advanced lung cancer feel better and improve their outcomes.

  Recruiting at 2 sites Phase 2 Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT05696782

• Combination treatment for advanced bile duct cancer

  This study is testing a new combination treatment for patients with advanced bile duct cancer that can't be surgically removed to see if it helps them feel better and live longer.

  Recruiting Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT05655949

• Durvalumab with chemotherapy before surgery for biliary tract cancer

  This phase II trial tests a combination of durvalumab with gemcitabine, cisplatin, and nab-paclitaxel before surgery in people with resectable biliary tract cancer to see if it helps shrink tumors and improve outcomes.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT05640791

• Combination treatment for advanced gastric cancer with MET amplification

  This study is testing a new combination treatment of durvalumab and savolitinib for patients with advanced gastric cancer who have not responded to previous chemotherapy and have a specific genetic change called MET amplification.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT05620628

• Restoring immunotherapy sensitivity in advanced triple negative breast cancer

  This study is testing a new combination of treatments to see if it can help people with advanced triple negative breast cancer whose tumors have come back after earlier treatments.

  Recruiting at 6 sites Phase 2 IFOM ETS - The AIRC Institute of Molecular Oncology · Novara, Novara and 5 other locations · NCT05582538

• Comparing standard chemotherapy with immune-based combinations for relapsed stage III non-small-cell lung cancer after chemoradiotherapy and durvalumab

  This study tests whether adding durvalumab to second-line single-agent chemotherapy, or adding olaparib to durvalumab, helps people with stage III non-small-cell lung cancer who relapse after chemoradiotherapy and durvalumab live longer.

  Recruiting Phase 2 Fondazione Ricerca Traslazionale · Roma, RM · NCT05568212

• Combination treatment of Durvalumab and Tremelimumab for liver cancer before surgery

  This study is testing whether a combination of two immune treatments, Durvalumab and Tremelimumab, can help people with early to intermediate liver cancer do better before surgery.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario and 2 other locations · NCT05440864

• Combining chemotherapy and Yttrium-90 treatment for liver cancer

  This study is testing a new combination of chemotherapy and Yttrium-90 treatment to see if it can help people with liver cancer shrink their tumors and manage their disease better than standard treatments.

  Recruiting Phase 2 Inova Health Care Services · Fairfax, Virginia · NCT05422690

• Selumetinib plus ZEN-3694 with durvalumab for certain sarcomas and NF1-associated MPNST

  This trial tests a combination of medicines to see if they can help adults with unresectable or metastatic sarcomas, including NF1-associated MPNST.

  Recruiting Phase 2 University of Alabama at Birmingham · Birmingham, Alabama · NCT05253131

• Olaparib and Durvalumab for Biliary Tract Cancer after Chemotherapy

  This study is testing if the drugs Olaparib and Durvalumab can help people with advanced biliary tract cancer who have finished their first round of chemotherapy and have certain gene mutations.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT05222971

• Combining durvalumab with radiation for extensive-stage small cell lung cancer

  This study is testing if adding a new drug called durvalumab to radiation and chemotherapy can help people with extensive-stage small cell lung cancer live longer without their cancer getting worse.

  Recruiting Phase 2 University of Chicago · Chicago, Illinois and 1 other locations · NCT05068232

• Comparing two radiation therapy methods for lung cancer treatment

  This study is testing whether a new type of radiation therapy combined with chemotherapy and immunotherapy can help people with advanced non-small cell lung cancer do better than the standard treatment.

  Recruiting at 5 sites Phase 2 University of Kansas Medical Center · Kansas City, Kansas and 5 other locations · NCT04992780

• Combining local therapy and durvalumab for advanced lung cancer after initial treatment

  This study is testing whether combining local treatments like surgery or radiation with the immunotherapy durvalumab can help people with advanced lung cancer live longer and feel better after their initial treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04892953

• Predicting durvalumab toxicity using microbiome analysis in lung cancer patients

  This study is testing if the bacteria in the gut can help predict how bad the side effects will be for lung cancer patients taking durvalumab after their treatment.

  Recruiting University of Kansas Medical Center · Kansas City, Kansas and 1 other locations · NCT04680377

• Combination treatment of Olaparib and Durvalumab for advanced ovarian cancer

  This study is testing if a combination of two drugs, Olaparib and Durvalumab, can help people with advanced ovarian cancer feel better after their initial chemotherapy.

  Recruiting at 6 sites Phase 2 AGO Research GmbH · Mannheim, Baden-Wurttemberg and 5 other locations · NCT04644289

• Adding durvalumab to chemotherapy before surgery for high-grade upper urinary tract cancer

  This study is testing whether adding an immunotherapy drug called durvalumab to standard chemotherapy before surgery can help people with high-grade upper urinary tract cancer do better.

  Recruiting at 151 sites Phase 2/3 National Cancer Institute (NCI) · Kingman, Arizona and 257 other locations · NCT04628767

• Combining durvalumab and tremelimumab with chemotherapy for HIV-infected lung cancer patients

  This study is testing if a combination of two immune treatments with chemotherapy can help people with stage IV lung cancer who are also living with HIV.

  Recruiting at 4 sites Phase 2 Georgetown University · Washington D.C., District of Columbia and 3 other locations · NCT04499053

• Radiation therapy followed by immune therapy for advanced liver cancer

  This study is testing whether a combination of radiation therapy and immune treatments can help people with advanced liver cancer that hasn't improved after other treatments.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT04430452

• Combination of Durvalumab and Cancer Vaccine for Bladder Cancer

  This study is testing a new combination of a cancer vaccine and an immune therapy to see if it can help people with bladder cancer that hasn't responded to standard treatment.

  Recruiting at 7 sites Phase 1/2 University College, London · Cambridge and 6 other locations · NCT04106115

• Combining microbiota therapy with durvalumab and chemotherapy for lung cancer

  This study is testing if adding a special gut treatment to standard chemotherapy and durvalumab can help people with advanced lung cancer feel better and improve their treatment results.

  Recruiting at 9 sites Phase 2 Masonic Cancer Center, University of Minnesota · Phoenix, Arizona and 9 other locations · NCT04105270

• Combining durvalumab with chemotherapy for advanced solid tumors

  This study is testing if combining an immunotherapy drug called durvalumab with standard chemotherapy can help people with advanced solid tumors by improving their immune response and slowing down tumor growth.

  Recruiting Phase 2 National Cancer Institute (NCI) · Bethesda, Maryland · NCT03907475

• Treatment with durvalumab for cancer patients who had side effects from previous therapies

  This study is testing if the immunotherapy drug durvalumab, combined with prednisone, can help cancer patients who had side effects from previous treatments while also seeing if it can slow down their cancer.

  Recruiting at 10 sites Phase 2 Canadian Cancer Trials Group · Edmonton, Alberta and 10 other locations · NCT03847649

• AZD5363 with olaparib and durvalumab for advanced or metastatic solid tumors

  This trial tries giving AZD5363 together with olaparib and durvalumab to adults with advanced or metastatic solid tumors to see if the combination is safe and to find a tolerable dose.

  Recruiting Phase 1 National University Hospital, Singapore · Singapore, Singapore · NCT03772561

• Combining Durvalumab with Chemoradiotherapy for Stage III Lung Cancer

  This study is testing if adding Durvalumab to standard treatment can help people with stage III lung cancer have better outcomes before surgery.

  Recruiting Phase 1/2 Yonsei University · Seoul, Seoul · NCT03694236

• Combining a personalized vaccine with chemotherapy and immunotherapy for metastatic triple-negative breast cancer

  This study is testing if adding a personalized vaccine to chemotherapy and immunotherapy can help people with metastatic triple-negative breast cancer feel better and improve their treatment outcomes.

  Recruiting at 24 sites Phase 2 National Cancer Institute (NCI) · Orange, California and 29 other locations · NCT03606967

• Combining cabozantinib and durvalumab for advanced gastrointestinal cancers

  This study is testing a new combination of two cancer drugs, cabozantinib and durvalumab, to see if they can help people with advanced gastrointestinal cancers feel better and improve their outcomes.

  Recruiting Phase 1/2 University of Pittsburgh · Westwood, Kansas and 1 other locations · NCT03539822

• Durvalumab with pralatrexate, romidepsin, or oral 5‑azacitidine for peripheral T‑cell lymphoma

  This trial will test several combinations of durvalumab with pralatrexate, romidepsin, and/or oral 5‑azacitidine to find safe doses and see if they help adults with newly diagnosed or relapsed peripheral T‑cell lymphoma.

  Recruiting Phase 1/2 University of Virginia · Charlottesville, Virginia · NCT03161223

• Durvalumab With or Without Lenalidomide for Relapsed/Refractory Cutaneous or Peripheral T-Cell Lymphoma

  This study tests whether adding lenalidomide to durvalumab is safe and helps treating relapsed or refractory cutaneous or peripheral T-cell lymphoma.

  Recruiting Phase 1/2 City of Hope Medical Center · Duarte, California and 3 other locations · NCT03011814

Quick answers

How many clinical trials of Durvalumab are recruiting right now?

104, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 48 countries. The most sites are in United States (47 trials), China (18 trials), Italy (17 trials), France (14 trials), South Korea (14 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 67, Phase 3: 10, Phase 1/2: 9, Phase 1: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →